ELVN Key Statistics, Chart & Performance
The current stock price of ELVN is 29.42 USD. In the past month the price increased by 26.54%. In the past year, price increased by 33.73%.
ELVN Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to ELVN. When comparing the yearly performance of all stocks, ELVN is one of the better performing stocks in the market, outperforming 92.66% of all stocks.
ELVN Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ELVN. ELVN has a great financial health rating, but its profitability evaluates not so good.
ELVN Financial Highlights
Over the last trailing twelve months ELVN reported a non-GAAP Earnings per Share(EPS) of -1.84. The EPS increased by 3.16% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -19.8% | ||
| ROE | -20.42% | ||
| Debt/Equity | 0 |
ELVN Forecast & Estimates
16 analysts have analysed ELVN and the average price target is 41.59 USD. This implies a price increase of 41.38% is expected in the next year compared to the current price of 29.42.
ELVN Ownership
ELVN Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 31.53 | 965.082B | ||
| JNJ | JOHNSON & JOHNSON | 20.76 | 572.907B | ||
| MRK | MERCK & CO. INC. | 22.54 | 297.222B | ||
| PFE | PFIZER INC | 9.06 | 150.614B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 10.19 | 121.168B | ||
| ZTS | ZOETIS INC | 18.6 | 55.849B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.61 | 25.456B | ||
| VTRS | VIATRIS INC | 5.78 | 16.516B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.9 | 12.079B | ||
| AXSM | AXSOME THERAPEUTICS INC | 223.48 | 9.116B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ELVN
Company Profile
Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery and development of small molecule therapeutics. The company is headquartered in Boulder, Colorado and currently employs 65 full-time employees. The company went IPO on 2020-03-12. The company is advancing two parallel lead product candidates, ELVN-001 and ELVN-002, and pursuing several additional research stage opportunities that align with its development approach. Its first product candidate, ELVN-001, is a potent, highly selective, small molecule kinase inhibitor designed to specifically target the breakpoint cluster region-Abelson (BCR-ABL) gene fusion, the oncogenic driver for patients with chronic myeloid leukemia. Its second product candidate, ELVN-002, is a potent, highly selective, central nervous system penetrant and irreversible human epidermal growth factor receptor 2 (HER2) inhibitor with activity against wild type HER2 and various HER2 mutations. ELVN-002 is designed to inhibit wild type HER2 and key mutations of HER2, while sparing wild-type EGFR and avoiding EGFR-related toxicities.
Company Info
ENLIVEN THERAPEUTICS INC
6200 Lookout Road
Boulder COLORADO US
Employees: 65
Phone: 17206478519
ENLIVEN THERAPEUTICS INC / ELVN FAQ
What does ELVN do?
Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery and development of small molecule therapeutics. The company is headquartered in Boulder, Colorado and currently employs 65 full-time employees. The company went IPO on 2020-03-12. The company is advancing two parallel lead product candidates, ELVN-001 and ELVN-002, and pursuing several additional research stage opportunities that align with its development approach. Its first product candidate, ELVN-001, is a potent, highly selective, small molecule kinase inhibitor designed to specifically target the breakpoint cluster region-Abelson (BCR-ABL) gene fusion, the oncogenic driver for patients with chronic myeloid leukemia. Its second product candidate, ELVN-002, is a potent, highly selective, central nervous system penetrant and irreversible human epidermal growth factor receptor 2 (HER2) inhibitor with activity against wild type HER2 and various HER2 mutations. ELVN-002 is designed to inhibit wild type HER2 and key mutations of HER2, while sparing wild-type EGFR and avoiding EGFR-related toxicities.
What is the stock price of ENLIVEN THERAPEUTICS INC today?
The current stock price of ELVN is 29.42 USD. The price increased by 9% in the last trading session.
Does ENLIVEN THERAPEUTICS INC pay dividends?
ELVN does not pay a dividend.
What is the ChartMill rating of ENLIVEN THERAPEUTICS INC stock?
ELVN has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the market cap for ENLIVEN THERAPEUTICS INC?
ENLIVEN THERAPEUTICS INC (ELVN) has a market capitalization of 1.75B USD. This makes ELVN a Small Cap stock.
Can you provide the ownership details for ELVN stock?
You can find the ownership structure of ENLIVEN THERAPEUTICS INC (ELVN) on the Ownership tab.